Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD79a Antikörper (AA 202-216)

CD79A Reaktivität: Human FACS, IF, WB, IHC Wirt: Maus Monoclonal JCB117 unconjugated
Produktnummer ABIN6252444
  • Target Alle CD79a (CD79A) Antikörper anzeigen
    CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
    Bindungsspezifität
    • 69
    • 24
    • 10
    • 10
    • 8
    • 7
    • 7
    • 6
    • 6
    • 5
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 202-216
    Reaktivität
    • 187
    • 101
    • 80
    • 51
    • 50
    • 32
    • 27
    • 25
    • 25
    • 25
    • 16
    • 9
    • 5
    • 5
    • 2
    • 1
    Human
    Wirt
    • 102
    • 99
    • 3
    • 1
    Maus
    Klonalität
    • 122
    • 82
    • 1
    Monoklonal
    Konjugat
    • 89
    • 19
    • 16
    • 15
    • 14
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CD79a Antikörper ist unkonjugiert
    Applikation
    • 116
    • 94
    • 61
    • 58
    • 46
    • 22
    • 21
    • 14
    • 9
    • 5
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF), Western Blotting (WB), Immunohistochemistry (IHC)
    Aufreinigung
    Protein G affinity chromatography
    Immunogen
    Amino acids 202-216 (GTYQDVGSLNIADVQ) were used as the immunogen for this CD79a antibody.
    Klon
    JCB117
    Isotyp
    IgG1 kappa
    Top Product
    Discover our top product CD79A Primärantikörper
  • Applikationshinweise
    Flow Cytometry: 0.5-1 μg/million cells

    IF: 0.5-1 μg/mL

    IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1)

    Prediluted format : incubate for 30 min at RT (2)

    The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD79a antibody to be titered up or down for optimal performance.

    1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
    2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.2 mg/mL
    Buffer
    PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Aliquot and Store at -20C. Avoid freez-thaw cycles.
  • Target
    CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
    Andere Bezeichnung
    CD79a (CD79A Produkte)
    Synonyme
    CD79A antikoerper, Ig-alpha antikoerper, Iga antikoerper, Igalpha antikoerper, Ly-54 antikoerper, Ly54 antikoerper, mb-1 antikoerper, IGA antikoerper, MB-1 antikoerper, IG-alpha antikoerper, CD79a molecule antikoerper, CD79A antigen (immunoglobulin-associated alpha) antikoerper, Cd79a molecule-like antikoerper, CD79A antikoerper, Cd79a antikoerper, Cd79al antikoerper
    Hintergrund
    A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B-cell Ag receptor. CD79a first appears at pre B-cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. It is found in the majority of acute leukemias of B-cell precursors, lines and lymphomas, and in some myelomas. It is not present in myeloid or Tcell lines. CD79a antibody is generally used to complement CD20 mAb, especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This CD79a antibody will stain many of the same lymphomas as CD20 mAb, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 mAb. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
    Gen-ID
    973
    UniProt
    P11912
    Pathways
    BCR Signaling
Sie sind hier:
Kundenservice